Investors

Corporate Profile

Edge Therapeutics is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize novel, hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening conditions.

We believe EG-1962, our lead product candidate, can fundamentally improve patient outcomes and transform the management of aneurysmal subarachnoid hemorrhage, or aSAH, which is bleeding around the brain due to a ruptured brain aneurysm. Read More

Lastest News

December 9, 2016 - Edge Therapeutics Announces Publication of Phase 1/2 Data on EG-1962 for the Treatment of Aneurysmal Subarachnoid Hemorrhage in Peer-Reviewed Medical Journal, Stroke
Read More
November 2, 2016 - Edge Therapeutics to Present at Investor Conferences in November
Read More
November 1, 2016 - Edge Therapeutics Reports Third Quarter Financial Results
Read More

Upcoming Events

There are currently no events scheduled.

Stock Information

EDGE (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$11.01
Change (%) Stock is Up 0.14 (1.29%)
Volume20,332
Data as of January 20, 2017 4:00 p.m. ET
Refresh quote

IR Contact

Gregory Gin
Email: ir@edgetherapeutics.com

Data provided by Nasdaq. Minimum 15 minutes delayed.

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR ContactsDownload Financial Tear Sheet Financial Tear Sheet